Acquisition - April 19, 2016
AZ explore potential takeover of Medivation
The Sunday Times reports that AstraZeneca has held “internal talks” regarding a potential bid for Medivation, but the company has not yet made a formal proposal, reported the magazine and citing unnamed sources. According to the newspaper, AstraZeneca has been tracking Medivation for the past six months, while a senior healthcare banker is quoted as saying […]
Acquisition - April 19, 2016
Xvivo makes recommended public bid for Vivoline
The Swedish company Xvivo Perfusion has made a recommended public offer to holders of shares in Vivoline Medical. The company offers for every share in Vivoline 1.2921 Swedish crown in cash and 0.1543 shares in Xvivo Perfusion. The consideration corresponds to a value of about 9.32 Swedish crowns per share. The company says the total value of […]
Acquisition - April 16, 2016
Recipharm creates global CDMO through new acquisitions
Swedish CDMO Recipharm continues to expand. Most recently the company acquired Kemwell’s pharmaceutical CDMO businesses. In February Recipharm acquired privately owned Italian CDMO Mitim, adding important technology in the filling of injectable beta lactams with sales to the US and European markets. The transaction is valued at an enterprise value of EUR 68 million. The […]
Acquisition - April 11, 2016
CareDx closes deal with Allenex
CareDx’s offer to the shareholders of Swedish Allenex has been accepted by shareholders holding an aggregate of 118,207,862 shares, corresponding to approximately 98.3% of the total number of shares in Allenex. CareDx declares the offer unconditional and completes the offer. The settlement is expected to occur on or around April 13, 2016. On December 16, […]
Acquisition - April 8, 2016
BioSilta acquires worldwide rights to CyDisCo
BioSilta, a privately-held company that utilizes its EnBase technology platform to develop reagent-based EnPresso bacterial and yeast expression culture systems, has acquired a license to worldwide exclusive rights to CyDisCo (Cytoplasmic Disulphide bond formation in E. coli) protein production technology from the University of Oulu. This license agreement will enable BioSilta will combine its EnPresso culture […]
Acquisition - April 5, 2016
Pila Pharma acquires Ario Pharma’s TRPV1 assets
The Malmö based “micro-pharma” aiming at developing innovative new approaches to treat diabetes, PILA PHARMA has acquired XEN-D0501, a clinical ready and safe TRPV1 antagonist development candidate, previously owned by Ario Pharma. The acquired asset include a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data. The TRPV1 target (also called […]
